Vivos Therapeutics, Inc. Earnings Recaps
Q3 2025
Nov 21, 2025
Vivos experienced a landmark third quarter 2025, reporting a 76% year-over-year revenue increase to $6.8 million, driven by the successful integration of the Sleep Center of Nevada.
Key takeaways
- Revenue from OSA sleep testing services surged by $2.2 million, primarily from the newly acquired SCN and two treatment centers in Las Vegas.
- The company's gross profit increased to $3.9 million, with a gross margin of 58%, despite rising costs linked to SCN integration.
- VIP enrollment revenue from the legacy model decreased by $800,000, confirming a strategic pivot toward a more sustainable revenue stream through service and product offerings.
- Year-to-date revenue increased by 20% to $13.6 million, highlighting strong momentum following the acquisition.
- General and administrative expenses rose 42% to $19.2 million, primarily due to increased costs from SCN operations.